Treatment of Persistent Depressive Disorder

First-Line Pharmacotherapy Selection

The American College of Physicians recommends selecting second-generation antidepressants, such as SSRIs or SNRIs, based on adverse effect profiles, cost, and patient preferences, as no single agent demonstrates superior efficacy over another 1, 2
The evidence for dysthymia treatment specifically shows mixed results across fluoxetine, paroxetine, and sertraline, but all demonstrate benefit over placebo, with the strength of evidence being moderate to high 1
Choosing among second-generation antidepressants without prioritizing one over another for efficacy is recommended, as they show equivalent effectiveness, according to the American Psychiatric Association 1, 2

Starting with an SSRI, such as fluoxetine, sertraline, citalopram, or escitalopram, as first-line treatment is recommended, with a strength of evidence being high 1, 2
If sexual dysfunction is a concern, choosing bupropion, which has lower rates of sexual adverse events compared to SSRIs, is recommended, based on moderate to high strength of evidence 1
If cost is a primary factor, selecting generic SSRIs, such as fluoxetine, sertraline, or citalopram, over newer agents is recommended, with a strength of evidence being moderate 1, 2

Paroxetine carries higher rates of sexual dysfunction than fluoxetine, fluvoxamine, nefazodone, or sertraline and should be avoided as first-line unless other factors dictate its use, based on high strength of evidence 1
SSRIs increase risk for nonfatal suicide attempts compared to placebo, requiring close monitoring especially during initial treatment, with a strength of evidence being high 1

Assessing patient status, therapeutic response, and adverse effects within 1-2 weeks of initiating therapy is critical, according to the American Medical Association 2, 3
Monitoring suicidality risk, particularly with SSRIs, is essential, with a strength of evidence being high 1, 3
Identifying intolerable adverse effects requiring medication adjustment is crucial, based on moderate to high strength of evidence 1, 2

Continuing treatment for 4-9 months after satisfactory response for first episodes of dysthymia is recommended, according to the American Psychiatric Association, with a strength of evidence being moderate to high 2, 4
For patients with recurrent depression or two or more episodes, extending treatment duration to ≥1 year or longer is recommended, based on moderate to high strength of evidence 2, 4

Cognitive behavioral therapy (CBT) demonstrates equivalent effectiveness to second-generation antidepressants and should be considered, particularly for patients with mild to moderate symptoms, according to the American Psychological Association, with a strength of evidence being moderate to high 3
Combination therapy (psychotherapy plus antidepressant) produces superior outcomes compared to monotherapy for severe presentations, based on moderate to high strength of evidence 3